Streetbeat News

Price Targets

F

Morgan Stanley analyst Adam Jonas has maintained an Overweight rating on Ford Motor (NYSE:F) but has lowered the price target from $16 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:36 pm

WOOF

Wedbush analyst Seth Basham maintains an Outperform rating on Petco Health and Wellness (NASDAQ:WOOF) but lowers the price target from $6 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:36 pm

ETRN

Morgan Stanley analyst Devin McDermott has maintained an Overweight rating on Equitrans Midstream (ETRN) but lowered the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:35 pm

KMX

Wedbush analyst Seth Basham has reiterated an Outperform rating on CarMax (NYSE:KMX) and maintained a $90 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:35 pm

CLF

Morgan Stanley analyst Carlos De Alba has maintained an Overweight rating on Cleveland-Cliffs (NYSE:CLF) and raised the price target from $19 to $21.5.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:34 pm

VFC

Wedbush analyst Tom Nikic has maintained a Neutral rating on VF (NYSE:VFC) and lowered the price target from $20 to $15.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:33 pm

AXNX

Morgan Stanley analyst Cecilia Furlong has maintained an Overweight rating on Axonics (NASDAQ:AXNX) but lowered the price target from $76 to $69.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:33 pm

ACGL

Morgan Stanley analyst Michael Phillips has maintained an Overweight rating on Arch Capital Group (NASDAQ:ACGL) and raised the price target from $100 to $103.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:32 pm

VRDN

Wedbush analyst Laura Chico maintains an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) but lowers the price target from $46 to $37.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:30 pm

PEAK

Wedbush analyst Richard Anderson has reiterated a Neutral rating on Healthpeak Properties (NYSE:PEAK) and maintained a $19 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:28 pm